var data={"title":"Laronidase: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Laronidase: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6438?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=laronidase-drug-information\" class=\"drug drug_general\">see &quot;Laronidase: Drug information&quot;</a> and <a href=\"topic.htm?path=laronidase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Laronidase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6187724\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of anaphylaxis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Life-threatening anaphylactic reactions have been observed in some patients during laronidase infusions. Therefore, ensure that appropriate medical support is readily available when laronidase is administered. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise because of infusion reactions and may require additional monitoring.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187005\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aldurazyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854886\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aldurazyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048167\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Enzyme</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Mucopolysaccharidosis I (MPS I) Disease, Treatment Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048160\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=laronidase-drug-information\" class=\"drug drug_general\">see &quot;Laronidase: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedicate with antipyretic and/or antihistamines 1 hour prior to start of infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b> Mucopolysaccharidosis I (Hurler syndrome, Hurler-Scheie, and Scheie forms):</b> Infants &ge;6 months, Children, and Adolescents: IV: 0.58 mg/kg/dose once weekly; dose should be rounded up to the nearest whole vial</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Mucopolysaccharidosis I (Hurler syndrome, Hurler-Scheie, and Scheie forms):</b> IV: 0.58 mg/kg/dose once weekly; dose should be rounded up to the nearest whole vial</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosing adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosing adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186987\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aldurazyme: 2.9 mg/5 mL (5 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186974\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048170\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV infusion: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Determine the number of vials to be diluted. Remove vials from the refrigerator and allow them to reach room temperature. Do not use if the solution is discolored or contains particulate matter. Determine the total infusion volume based on the patient's weight; for patients weighing &le;20 kg (or weighing up to 30 kg and with cardiac or respiratory compromise), dilute the required dose in 100 mL NS; for patients weighing &gt;20 kg, dilute required dose in 250 mL NS. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">From an NS infusion bag, remove and discard volume of NS equal to volume of laronidase injection solution to be added to the infusion bag. Add laronidase; do not agitate solution as it denatures the enzyme. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Administer using an infusion set with low protein-binding 0.2 micrometer in-line filter. Antipyretics and/or antihistamines should be administered 60 minutes prior to infusion. Volume and infusion rate are based on body weight; deliver infusion over ~3 to 4 hours. An initial 10 mcg/kg/hour infusion rate may be incrementally increased every 15 minutes during the first hour if tolerated (see below); increase to a maximum infusion rate of 200 mcg/kg/hour which is maintained for the remainder of the infusion (approximately 3 hours). Vital signs should be monitored every 15 minutes, if stable; in case of infusion-related reaction in any patient, decrease the rate of infusion, temporarily discontinue the infusion, and/or administer additional antipyretics/antihistamines. Manufacturer provides the following infusion rate information for patients receiving usual preparation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&le;20 kg: Total infusion volume: 100 mL </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">2 mL/hour for 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">4 mL/hour for 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">8 mL/hour for 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">16 mL/hour for 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">32 mL/hour for remainder of infusion (~3 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&gt;20 kg: Total infusion volume: 250 mL </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">5 mL/hour for 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">10 mL/hour for 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">20 mL/hour for 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">40 mL/hour for 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">80 mL/hour for remainder of infusion (~3 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> A total infusion volume of 100 mL NS and slower infusion rate may be considered for patients with cardiac or respiratory compromise who weigh up to 30 kg. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187000\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Do not shake. Following dilution in NS, solution for infusion should be used immediately; however, if not used immediately, diluted solutions should be refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 36 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048169\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of patients with Hurler and Hurler-Scheie forms of mucopolysaccharidosis I (MPS I), and patients with the Scheie form who have moderate to severe symptoms (FDA approved in ages &ge;6 months and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187024\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Unless otherwise noted, adverse reactions were reported in patients &ge;6 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, edema, facial edema, flushing, hot and cold flashes, hypertension (infants and children 6 months to 5 years), hypotension, oxygen saturation decreased (infants and children 6 months to 5 years), tachycardia (infants and children 6 months to 5 years), venous irritation (poor venous access: 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills (infants and children 6 months to 5 years: 20%), headache, hyperreflexia, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: hyperhidrosis, pallor (infants and children 6 months to 5 years), pruritus, skin rash (less frequent in infants and children 6 months to 5 years), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, abdominal distress, diarrhea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Severe hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Abscess at injection site, injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: arthralgia, back pain, musculoskeletal pain, tremor (infants and children 6 months to 5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Corneal opacity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media (infants and children 6 months to 5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory:  Bronchospasm, cough, dyspnea, rales (infants and children 6 months to 5 years), respiratory distress (infants and children 6 months to 5 years), upper respiratory tract infection, wheezing (infants and children 6 months to 5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (more common in infants and children 6 months to 5 years), infusion-related reaction (may be severe; less common in infants and children 6 months to 5 years),</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, angioedema, cardiac failure, cyanosis, erythema, pneumonia, respiratory failur</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186992\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed within the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Severe hypersensitivity to laronidase or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186978\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: <b>[US Boxed Warning]: Anaphylactic reactions have been observed during infusion, immediate treatment for hypersensitivity reactions should be available during administration. Additional monitoring may be required in patients with compromised respiratory function or acute respiratory disease; may be at increased risk for acute exacerbation of respiratory symptoms due to infusion reaction.</b> Reactions, which may include airway obstruction, bradycardia, bronchospasm, hypotension, hypoxia, respiratory distress/failure, stridor, tachypnea, and urticaria, may be severe and tend to occur during or within 3 hours after administration. Immediately discontinue infusion if severe reactions occur; medical support should be available during administration. Risks and benefits should be carefully considered prior to readministration following a severe hypersensitivity reaction. Patients who initially experience severe reactions may require prolonged monitoring. In the case of anaphylaxis, caution should be used if epinephrine is being considered; many patients with MPS I have pre-existing heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion reactions may occur; use caution and consider delaying treatment in patients with acute febrile/respiratory illness; may result in increased risk for infusion-related reactions. Pretreatment with antipyretics and antihistamines is recommended. Decrease infusion rate, temporarily discontinue infusion, and/or administer additional antipyretics and antihistamines to manage infusion reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Use with caution in patients at risk for fluid overload or in conditions where fluid restriction is indicated (eg, acute underlying respiratory illness, compromised cardiac and/or respiratory function); conditions may be exacerbated during infusion. Extended observation may be necessary for some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; MPS I: Appropriate use: Has not been studied in patients with mild symptoms of the Scheie form of MPS I. Not indicated for the CNS manifestations of the disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep apnea: Use with caution in patients with sleep apnea; evaluate patients prior to initiation of therapy. Apnea treatment options should be readily available (eg, CPAP or supplemental oxygen) during infusion or with use of sedating antihistamines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Registry: A patient registry has been established and all patients are encouraged to participate. Registry information may be obtained at www.MPSIregistry.com or by calling 800-745-4447.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299577\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186981\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13320&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186983\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186994\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies. Patients are encouraged to enroll in the MPS I registry (800-745-4447 or www.MPSIregistry.com). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048166\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs, FVC, height, weight, range of motion, serum antibodies to &alpha;-L-iduronidase, urine levels of glycosaminoglycans (GAG), change in liver size</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186977\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Laronidase is a recombinant (replacement) form of alpha-L-iduronidase derived from Chinese hamster cells. Alpha-L-iduronidase is an enzyme needed to break down endogenous glycosaminoglycans (GAGs) within lysosomes. A deficiency of alpha-L-iduronidase leads to an accumulation of GAGs, causing cellular, tissue, and organ dysfunction as seen in MPS I. Improved pulmonary function and walking capacity have been demonstrated with the administration of laronidase to patients with Hurler, Hurler-Scheie, or Scheie (with moderate-to-severe symptoms) forms of MPS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186991\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 6 months to 5 years: V<sub>d</sub>: 0.12-0.56 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;6 years and Adults: V<sub>d</sub>: 0.24-0.6 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 6 months to 5 years: 0.3-1.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;6 years and Adults: 1.5-3.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 6 months to 5 years: Clearance: 2.2-7.7 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;6 years and Adults: Clearance: 1.7-2.7 mL/minute/kg; during the first 12 weeks of therapy the clearance of laronidase increases proportionally to the amount of antibodies a given patient develops against the enzyme. However, with long-term use (&ge;26 weeks) antibody titers have no effect on laronidase clearance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323284\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aldurazyme Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.9 mg/5 mL (5 mL): $1,005.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038666\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldurazym (UA);</li>\n      <li>Aldurazyme (AT, AU, BB, BE, BG, BR, CH, CL, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, IE, IL, IT, JP, KR, LT, LU, LV, MT, MY, NL, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TH, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aldurazyme (laronidase) [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc; April 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/laronidase-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/laronidase-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kakkis ED, Muenzer J, Tiller GE, et al, &ldquo;Enzyme-Replacement Therapy in Mucopolysaccharidosis I,&rdquo; <i>N Engl J Med</i>, 2001, 344(3):182-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/laronidase-pediatric-drug-information/abstract-text/11172140/pubmed\" target=\"_blank\" id=\"11172140\">11172140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13320 Version 89.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6187724\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187005\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F854886\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048167\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048160\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F186987\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F186974\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048170\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F187000\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048169\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187024\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F186992\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F186978\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299577\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F186981\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F186983\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F186994\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048166\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F186977\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F186991\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323284\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038666\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13320|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=laronidase-drug-information\" class=\"drug drug_general\">Laronidase: Drug information</a></li><li><a href=\"topic.htm?path=laronidase-patient-drug-information\" class=\"drug drug_patient\">Laronidase: Patient drug information</a></li></ul></div></div>","javascript":null}